Skip Navigation
 
 
 
 xxx
 
 
 
 
 
 
 
 
 
Print This Page
Share this page: More
 

Jacques Grosset, M.D.

Jacques Henri Edmond Grosset, M.D.
Professor, Center for Tuberculosis Research

Jacques Grosset, M.D.


Read Complete CV.
Email Dr. Grosset

M. tuberculosis still infects over 1.7 billion people, causes disease in over 8 million people every year, and kills more than 2 million people every year. Since the beginning of my professional life I have been involved in research to improve the control of tuberculosis, mainly by improving treatment of tuberculosis and preventing the development of drug resistance.

Tuberculosis was a leading cause of death in industrialized countries when I started my medical studies. Despite the tremendous progress made during the past half-century,

During the past 45 years, I have participated in the development of nearly all new drug regimens used for tuberculosis and a number of other mycobacterial diseases, namely leprosy, M. avium complex infection in HIV-infected persons, and M. ulcerans infection (Buruli ulcer). Using the murine experimental model, I directed the development of an antibiotic regimen that led to the first clinical that demonstrated the efficacy of this treatment for Buruli ulcer. I also participated in the design and evaluation of this trial. At present, my primary involvement is in the use of the mouse model to investigate the efficacy of new drugs and new drug combinations in human diseases caused by mycobacteria for improving both the efficacy of treatment and the implementation of Directly Observed Therapy (DOT) with the main following objectives:

  1. Shorten the duration of therapy
  2. Increase the interval between dosing by using drugs with long half lives and/or slow release preparations

Any investigator involved in the study of antituberculous chemotherapy must grapple with 2 phenomena unique to the pathogenesis and treatment of tuberculosis. The first is a propensity for the initial infection to evolve under the pressure of host immunity into a paucibacillary latent state which may reactivate into clinical disease at a later point in time.

The second is a capacity for persistence of a small bacillary population in a state of unresponsiveness to antimicrobials to which they are genotypically susceptible. The mechanisms by which the bacteria transition to and survive in the latent and persistent states are unknown. Therefore, the identification of bacterial factors involved in both states would be extremely beneficial for both the preventive and the curative therapy of tuberculosis. The genomics revolution has provided the tools and techniques necessary to begin to identify those bacterial factors regulating the adaptive response. My collaboration with Dr. William Bishai, a recognized expert in the field of mycobacterial genetics and pathogenesis, offers a unique opportunity to address these crucial issues.

Publications

To read some of these publications online, click here. Please note that to read the full text of some of these articles requires that you have an online subscription to the journal.

1.    Williams, K. N., C. K. Stover, T. Zhu, R. Tasneen, S. Tyagi, J. H. Grosset, and E. Nuermberger. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 53:1314-9.
2.    Makarov, V., G. Manina, K. Mikusova, U. Mollmann, O. Ryabova, B. Saint-Joanis, N. Dhar, M. R. Pasca, S. Buroni, A. P. Lucarelli, A. Milano, E. De Rossi, M. Belanova, A. Bobovska, P. Dianiskova, J. Kordulakova, C. Sala, E. Fullam, P. Schneider, J. D. McKinney, P. Brodin, T. Christophe, S. Waddell, P. Butcher, J. Albrethsen, I. Rosenkrands, R. Brosch, V. Nandi, S. Bharath, S. Gaonkar, R. K. Shandil, V. Balasubramanian, T. Balganesh, S. Tyagi, J. Grosset, G. Riccardi, and S. T. Cole. 2009. Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis. Science 32:801-4.
3.    Converse, P. J., P. C. Karakousis, L. G. Klinkenberg, A. K. Kesavan, L. H. Ly, S. S. Allen, J. H. Grosset, S. K. Jain, G. Lamichhane, Y. C. Manabe, D. N. McMurray, E. L. Nuermberger, and W. R. Bishai. 2009. Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun 77:1230-7.
4.    Tasneen, R., S. Tyagi, K. Williams, J. Grosset, and E. Nuermberger. 2008. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 52:3664-8.
5.    Rosenthal, I. M., M. Zhang, D. Almeida, J. H. Grosset, and E. L. Nuermberger. 2008. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 178:989-93.
6.    Nuermberger, E., S. Tyagi, R. Tasneen, K. N. Williams, D. Almeida, I. Rosenthal, and J. H. Grosset. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52:1522-4.
7.    Be, N. A., G. Lamichhane, J. Grosset, S. Tyagi, Q. J. Cheng, K. S. Kim, W. R. Bishai, and S. K. Jain. 2008. Murine model to study the invasion and survival of Mycobacterium tuberculosis in the central nervous system. J Infect Dis 198:1520-8.
8.    Rosenthal, I. M., K. Williams, S. Tyagi, C. A. Peloquin, A. A. Vernon, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2006. Potent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis. Am J Respir Crit Care Med 174:94-101.
9.    Nuermberger, E., I. Rosenthal, S. Tyagi, K. N. Williams, D. Almeida, C. A. Peloquin, W. R. Bishai, and J. H. Grosset. 2006. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 50:2621-5.
10.    Tyagi, S., E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 49:2289-93.
11.    Rosenthal, I. M., K. Williams, S. Tyagi, A. A. Vernon, C. A. Peloquin, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2005. Weekly Moxifloxacin and Rifapentine is More Active than the Denver Regimen in Murine Tuberculosis. Am J Respir Crit Care Med.
12.    Nuermberger, E., S. Tyagi, K. N. Williams, I. Rosenthal, W. R. Bishai, and J. H. Grosset. 2005. Rifapentine, Moxifloxacin or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am J Respir Crit Care Med.
13.    Maugein, J., M. Dailloux, B. Carbonnelle, V. Vincent, and J. Grosset. 2005. Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease. Eur Respir J 26:1092-6.
14.    Ginsburg, A. S., R. Sun, H. Calamita, C. P. Scott, W. R. Bishai, and J. H. Grosset. 2005. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob Agents Chemother 49:3977-9.
15.    Ginsburg, A. S., J. Lee, S. C. Woolwine, J. H. Grosset, F. M. Hamzeh, and W. R. Bishai. 2005. Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Antimicrob Agents Chemother 49:853-6.
16.    Etuaful, S., B. Carbonnelle, J. Grosset, S. Lucas, C. Horsfield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, G. K. Amedofu, P. Awuah, E. Ampadu, G. Amofah, K. Asiedu, and M. Wansbrough-Jones. 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49:3182-6.
17.    Casal, M., M. Vaquero, H. Rinder, E. Tortoli, J. Grosset, S. Rusch-Gerdes, J. Gutierrez, and V. Jarlier. 2005. A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries. Microb Drug Resist 11:62-7.
18.    Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R. J. O'Brien, A. A. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170:1131-4.
19.    Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. O'Brien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169:421-6.
20.    Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, W. R. Bishai, and J. H. Grosset. 2004. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun 72:1065-71.
21.    Nuermberger, E., and J. Grosset. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 23:243-55.
22.    Karakousis, P. C., T. Yoshimatsu, G. Lamichhane, S. C. Woolwine, E. L. Nuermberger, J. Grosset, and W. R. Bishai. 2004. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 200:647-57.
23.    Quy, H. T., N. T. Lan, M. W. Borgdorff, J. Grosset, P. D. Linh, L. B. Tung, D. van Soolingen, M. Raviglione, N. V. Co, and J. Broekmans. 2003. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis 7:631-6.
24.    Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. O'Brien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2003. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med.
25.    Lounis, N., C. Maslo, C. Truffot-Pernot, J. Grosset, and R. J. Boelaert. 2003. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. Int J Tuberc Lung Dis 7:575-9.
26.    Lamichhane, G., M. Zignol, N. J. Blades, D. E. Geiman, A. Dougherty, J. Grosset, K. W. Broman, and W. R. Bishai. 2003. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 100:7213-8.
27.    Grosset, J. 2003. Mycobacterium tuberculosis in the Extracellular Compartment: an Underestimated Adversary. Antimicrob. Agents Chemother. 47:833-836.
28.    Ginsburg, A. S., J. H. Grosset, and W. R. Bishai. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 3:432-42.
29.    Emmanuelli, X., and J. Grosset. 2003. [Tuberculosis and poverty]. Rev Mal Respir 20:169-71.
30.    Yoshimatsu, T., E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset. 2002. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 46:1875-9.
31.    Grosset, J., L. Zunic, and C. Morcrette. 2002. [World epidemiology of tuberculosis and resistance against anti-tuberculosis drugs]. Ann Med Interne (Paris) 153:107-12.
32.    Dega, H., A. Bentoucha, J. Robert, V. Jarlier, and J. Grosset. 2002. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 46:3193-6.
33.    Lounis, N., C. Truffot-Pernot, J. Grosset, V. R. Gordeuk, and J. R. Boelaert. 2001. Iron and Mycobacterium tuberculosis infection. J Clin Virol 20:123-6.
34.    Lounis, N., C. Truffot-Pernot, A. Bentoucha, J. Robert, B. Ji, and J. Grosset. 2001. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother 45:3229-30.
35.    Lounis, N., A. Bentoucha, C. Truffot-Pernot, B. Ji, R. J. O'Brien, A. Vernon, G. Roscigno, and J. Grosset. 2001. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 45:3482-6.
36.    Honore, N., P. W. Roche, J. H. Grosset, and S. T. Cole. 2001. A method for rapid detection of rifampicin-resistant isolates of Mycobacterium leprae. Lepr Rev 72:441-8.
37.    Grosset, J. H., and S. T. Cole. 2001. Genomics and the chemotherapy of leprosy. Lepr Rev 72:429-40.
38.    Grosset, J. H. 2001. Newer drugs in leprosy. Int J Lepr Other Mycobact Dis 69:S14-8.
39.    Boelaert, J. R., R. Appelberg, M. S. Gomes, E. Blasi, R. Mazzolla, J. Grosset, N. Lounis, K. Soteriadou, M. Thiakaki, D. Taramelli, and C. Tognazioli. 2001. Experimental results on chloroquine and AIDS-related opportunistic infections. J Acquir Immune Defic Syndr 26:300-1.
40.    Bentoucha, A., J. Robert, H. Dega, N. Lounis, V. Jarlier, and J. Grosset. 2001. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 45:3109-12.
41.    Astagneau, P., N. Desplaces, V. Vincent, V. Chicheportiche, A. Botherel, S. Maugat, K. Lebascle, P. Leonard, J. Desenclos, J. Grosset, J. Ziza, and G. Brucker. 2001. Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet 358:747-51.
42.    Robert, J., D. Trystram, C. Truffot-Pernot, B. Carbonnelle, and J. Grosset. 2000. Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group. Int J Tuberc Lung Dis 4:665-72.
43.    Robert, J., D. Trystram, C. Truffot-Pernot, E. Cambau, V. Jarlier, and J. Grosset. 2000. Twenty-five years of tuberculosis in a French university hospital: a laboratory perspective. Int J Tuberc Lung Dis 4:504-12.
44.    Nguyen, L. N., J. L. Cartel, and J. H. Grosset. 2000. Chemoprophylaxis of leprosy in the southern Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 years. Lepr Rev 71:S33-5; discussion S35-6.
45.    Ji, B., and J. Grosset. 2000. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev 71:S81-7.
46.    Grosset, J. 2000. The new challenges for chemotherapy research. Lepr Rev 71:S100-4.
47.    Dega, H., J. Robert, P. Bonnafous, V. Jarlier, and J. Grosset. 2000. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 44:2367-72.
48.    Dega, H., O. Chosidow, S. Barete, B. Carbonnelle, J. Grosset, and V. Jarlier. 2000. [Mycobacterium ulcerans infection]. Ann Med Interne (Paris) 151:339-44.
49.    Daniel, N., N. Lounis, B. Ji, R. J. O'Brien, A. Vernon, L. J. Geiter, M. Szpytma, C. Truffot-Pernot, G. Hejblum, and J. Grosset. 2000. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. Am J Respir Crit Care Med 161:1572-7.
50.    Consigny, S., A. Bentoucha, P. Bonnafous, J. Grosset, and B. Ji. 2000. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother 44:2919-21.
51.    Cambau, E., C. Truffot-Pernot, F. Boulahbal, C. Wichlacz, J. Grosset, and V. Jarlier. 2000. Mycobacterial growth indicator tube versus the proportion method on Lowenstein-Jensen medium for antibiotic susceptibility testing of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 19:938-42.
52.    Robert, J., F. Boulahbal, D. Trystram, C. Truffot-Pernot, A. C. de Benoist, V. Vincent, V. Jarlier, and J. Grosset. 1999. A national survey of human Mycobacterium bovis infection in France. Network of Microbiology Laboratories in France. Int J Tuberc Lung Dis 3:711-4.
53.    Rinder, H., K. Feldmann, E. Tortoli, J. Grosset, M. Casal, E. Richter, M. Rifai, V. Jarlier, M. Vaquero, S. Rusch-Gerdes, E. Cambau, J. Gutierrez, and T. Loscher. 1999. Culture-independent prediction of isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum samples. Mol Diagn 4:145-52.
54.    Lounis, N., C. Truffot-Pernot, R. G. Ridley, G. Alber, and J. H. Grosset. 1999. Impacts of interleukin-12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in mice. Clin Microbiol Infect 5:331-338.
55.    Ji, B., and J. H. Grosset. 1999. Drugs and regimens for preventive therapy against tuberculosis, disseminated Mycobacterium avium complex infection and leprosy. Int J Lepr Other Mycobact Dis 67:S45-55.
56.    Grosset, J. 1999. [Leprosy and tuberculosis: opposite results?]. Med Trop (Mars) 59:25-30.
57.    Grosset, J. 1999. [Which strategies for eradication of tuberculosis?]. Bull Acad Natl Med 183:25-37; discussion 37-40.
58.    Flament-Saillour, M., J. Robert, V. Jarlier, and J. Grosset. 1999. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 160:587-93.
59.    Schwoebel, V., B. Decludt, A. C. de Benoist, S. Haeghebaert, G. Torrea, V. Vincent, and J. Grosset. 1998. Multidrug resistant tuberculosis in France 1992-4: two case-control studies. Bmj 317:630-1.
60.    Lemaitre, N., W. Sougakoff, C. Truffot-Pernot, E. Cambau, J. P. Derenne, F. Bricaire, J. Grosset, and V. Jarlier. 1998. Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a large urban hospital: detection of outbreaks in homeless people and migrant workers. Int J Tuberc Lung Dis 2:390-6.
61.    Jouveshomme, S., E. Cambau, D. Trystram, M. Szpytma, W. Sougakoff, J. P. Derenne, and J. Grosset. 1998. Clinical utility of an amplification test based on ligase chain reaction in pulmonary tuberculosis. Am J Respir Crit Care Med 158:1096-101.
62.    Ji, B., S. Sow, E. Perani, C. Lienhardt, V. Diderot, and J. Grosset. 1998. Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother 42:1115-20.
63.    Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 42:2066-9.
64.    Grosset, J. H., and S. Franzblau. 1998. Report of workshop on chemotherapy. Int J Lepr Other Mycobact Dis 66:595-6.
65.    Grosset, J., and C. Truffot-Pernot. 1998. [Mycobacterium xenopi, a newcomer?]. Rev Prat 48:701-3.
66.    Grosset, J., N. Lounis, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and B. Ji. 1998. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med 157:1436-40.
67.    Grosset, J. 1998. [What's new for tuberculosis in 1998?]. Rev Med Interne 19:613-6.
68.    Craft, J. C., G. F. Notario, J. H. Grosset, and L. B. Heifets. 1998. Clarithromycin resistance and susceptibility patterns of Mycobacterium avium strains isolated during prophylaxis for disseminated infection in patients with AIDS. Clin Infect Dis 27:807-12.
69.    Carbonne, A., N. Lemaitre, M. Bochet, C. Truffot-Pernot, C. Katlama, J. Grosset, F. Bricaire, and V. Jarlier. 1998. Mycobacterium avium complex common-source or cross-infection in AIDS patients attending the same day-care facility. Infect Control Hosp Epidemiol 19:784-6.
70.    Wyplosz, B., C. Truffot-Pernot, J. Robert, V. Jarlier, and J. Grosset. 1997. [The bacteriology of tuberculosis and non-tuberculosis mycobacterial infections]. Rev Mal Respir 14:S33-48.
71.    May, T., F. Brel, C. Beuscart, V. Vincent, C. Perronne, T. Doco-Lecompte, T. Saint-Marc, B. Dautzenberg, and J. Grosset. 1997. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clin Infect Dis 25:621-9.
72.    Mane, I., J. L. Cartel, and J. H. Grosset. 1997. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. Int J Lepr Other Mycobact Dis 65:224-9.
73.    Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1997. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother 41:607-10.
74.    Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1997. Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. Antimicrob Agents Chemother 41:1168-9.
75.    Ji, B., P. Jamet, S. Sow, E. G. Perani, I. Traore, and J. H. Grosset. 1997. High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Antimicrob Agents Chemother 41:1953-6.
76.    Iborra, C., E. Cambau, C. Lecomte, J. Grosset, F. Bricaire, and E. Caumes. 1997. [Cutaneous tuberculosis. A study of 4 cases]. Ann Dermatol Venereol 124:139-43.
77.    Grosset, J., and B. Ji. 1997. Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex. Drugs 54:23-7; discussion 28-9.
78.    Grosset, J. 1997. Whither short-course chemotherapy for leprosy? Indian J Lepr 69:119-20.
79.    Gimenez, F., V. Leblond, J. Nguyen, P. Serrand, J. L. Binet, J. Grosset, and A. Thuillier. 1997. Variations of teicoplanin concentrations in neutropenic patients. J Clin Pharm Ther 22:187-90.
80.    Dautzenberg, B., C. Truffot-Pernot, J. Hazebroucq, S. Legris, C. Guerin, C. Begelman, G. Guermonprez, M. H. Fievet, C. Chastang, and J. Grosset. 1997. A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections. Infection 25:16-21.
81.    Traore, I., B. Ji, C. Lienhardt, P. Bobin, and J. Grosset. 1996. Determination of the minimal effective dosages of ofloxacin and sparfloxacin against M. leprae in the mouse foot pad system. Int J Lepr Other Mycobact Dis 64:142-5.
82.    Lemaitre, N., W. Sougakoff, C. Truffot, J. Grosset, and V. Jarlier. 1996. [Analysis of restriction fragment length polymorphism (RFLP) of Mycobacterium tuberculosis strains isolated from patients with several episodes of tuberculosis]. Pathol Biol (Paris) 44:452-5.
83.    Lemaitre, N., W. Sougakoff, D. Coetmeur, J. Vaucel, V. Jarlier, and J. Grosset. 1996. Nosocomial transmission of tuberculosis among mentally-handicapped patients in a long-term care facility. Tuber Lung Dis 77:531-6.
84.    Ji, B., E. G. Perani, C. Petinom, and J. H. Grosset. 1996. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother 40:393-9.
85.    Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1996. How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? Antimicrob Agents Chemother 40:437-42.
86.    Ji, B., L. Levy, and J. H. Grosset. 1996. Chemotherapy of leprosy: progress since the Orlando Congress, and prospects for the future. Int J Lepr Other Mycobact Dis 64:S80-8; discussion S88-90.
87.    Ji, B., P. Jamet, E. G. Perani, S. Sow, C. Lienhardt, C. Petinon, and J. H. Grosset. 1996. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother 40:2137-41.
88.    Grosset, J. 1996. Current problems with tuberculosis treatment. Res Microbiol 147:10-6.
89.    Grosset, J. 1996. [Bacteriological diagnosis of tuberculosis]. Rev Prat 46:1337-43.
90.    Doucet-Populaire, F., V. Lalande, E. Carpentier, A. Bourgoin, M. Dailloux, C. Bollet, A. Vachee, D. Moinard, J. Texier-Maugein, B. Carbonnelle, and J. Grosset. 1996. A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Azay Mycobacteria Study Group. Tuber Lung Dis 77:358-62.
91.    Truffot-Pernot, C., N. Lounis, J. H. Grosset, and B. Ji. 1995. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 39:2827-8.
92.    Struillou, L., Y. Cohen, N. Lounis, G. Bertrand, J. Grosset, J. L. Vilde, J. J. Pocidalo, and C. Perronne. 1995. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. Antimicrob Agents Chemother 39:878-81.
93.    Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1995. Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. Antimicrob Agents Chemother 39:608-12.
94.    Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 39:1341-4.
95.    Grosset, J., and Y. Mouton. 1995. Is PCR a useful tool for the diagnosis of tuberculosis in 1995? Tuber Lung Dis 76:183-4.
96.    Enarson, D. A., J. Grosset, A. Mwinga, E. S. Hershfield, R. O'Brien, S. Cole, and L. Reichman. 1995. The challenge of tuberculosis: statements on global control and prevention. Lancet 346:809-19.
97.    Doucet-Populaire, F., C. Truffot-Pernot, J. Grosset, and V. Jarlier. 1995. Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. J Antimicrob Chemother 36:129-36.
98.    Cohen, Y., C. Perronne, T. Lazard, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1995. Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity. Antimicrob Agents Chemother 39:735-8.
99.    Chaulet, P., F. Boulahbal, and J. Grosset. 1995. Surveillance of drug resistance for tuberculosis control: why and how? Tuber Lung Dis 76:487-92.
100.    Baril, L., E. Caumes, C. Truffot-Pernot, F. Bricaire, J. Grosset, and M. Gentilini. 1995. Tuberculosis caused by Mycobacterium africanum associated with involvement of the upper and lower respiratory tract, skin, and mucosa. Clin Infect Dis 21:653-5.
101.    Xiong, J. H., B. Ji, E. G. Perani, C. Petinon, and J. H. Grosset. 1994. Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice. Int J Lepr Other Mycobact Dis 62:37-42.
102.    Vareldzis, B. P., J. Grosset, I. de Kantor, J. Crofton, A. Laszlo, M. Felten, M. C. Raviglione, and A. Kochi. 1994. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tuber Lung Dis 75:1-7.
103.    Schwoebel, V., B. Hubert, and J. Grosset. 1994. Tuberculous meningitis in France in 1990: characteristics and impact of BCG vaccination. Tuber Lung Dis 75:44-8.
104.    Lazard, T., C. Perronne, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1994. Chloroquine does not enhance the activity of clarithromycin against multiplication of Mycobacterium avium within human macrophages. Tuber Lung Dis 75:283-5.
105.    Ji, B., E. G. Perani, C. Petinom, L. N'Deli, and J. H. Grosset. 1994. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents Chemother 38:662-7.
106.    Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1994. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 38:2521-9.
107.    Heym, B., N. Honore, C. Truffot-Pernot, A. Banerjee, C. Schurra, W. R. Jacobs, Jr., J. D. van Embden, J. H. Grosset, and S. T. Cole. 1994. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 344:293-8.
108.    Grosset, J. H. 1994. Assessment of new therapies for infection due to the Mycobacterium avium complex: appropriate use of in vitro and in vivo testing. Clin Infect Dis 18:S233-6.
109.    Grosset, J. H. 1994. Progress in the chemotherapy of leprosy. Int J Lepr Other Mycobact Dis 62:268-77.
110.    Chapuis, L., B. Ji, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and J. H. Grosset. 1994. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med 150:1355-62.
111.    Cambau, E., W. Sougakoff, M. Besson, C. Truffot-Pernot, J. Grosset, and V. Jarlier. 1994. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 170:1351.
112.    Lazard, T., C. Perronne, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1993. Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. Antimicrob Agents Chemother 37:1690-2.
113.    Lazard, T., C. Perronne, Y. Cohen, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1993. Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. Antimicrob Agents Chemother 37:692-5.
114.    Lalande, V., C. Truffot-Pernot, A. Paccaly-Moulin, J. Grosset, and B. Ji. 1993. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 37:407-13.
115.    Ji, B., C. Truffot-Pernot, C. Lacroix, M. C. Raviglione, R. J. O'Brien, P. Olliaro, G. Roscigno, and J. Grosset. 1993. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 148:1541-6.
116.    Ji, B., P. Jamet, E. G. Perani, P. Bobin, and J. H. Grosset. 1993. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis 168:188-90.
117.    Honore, N., E. Perrani, A. Telenti, J. Grosset, and S. T. Cole. 1993. A simple and rapid technique for the detection of rifampin resistance in Mycobacterium leprae. Int J Lepr Other Mycobact Dis 61:600-4.
118.    Hejblum, G., V. Jarlier, J. Grosset, and A. Aurengo. 1993. Automated interpretation of disk diffusion antibiotic susceptibility tests with the radial profile analysis algorithm. J Clin Microbiol 31:2396-401.
119.    Glaziou, P., J. L. Cartel, J. P. Moulia-Pelat, L. N. Ngoc, S. Chanteau, R. Plichart, and J. H. Grosset. 1993. Tuberculosis in leprosy patients detected between 1902 and 1991 in French Polynesia. Int J Lepr Other Mycobact Dis 61:199-204.
120.    Dautzenberg, B., T. Saint Marc, M. C. Meyohas, M. Eliaszewitch, F. Haniez, A. M. Rogues, S. De Wit, L. Cotte, J. P. Chauvin, and J. Grosset. 1993. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 153:368-72.
121.    Schwoebel, V., B. Hubert, and J. Grosset. 1992. Impact of BCG on tuberculous meningitis in France in 1990. Lancet 340:611.
122.    Rouby, J. J., E. Martin De Lassale, P. Poete, M. H. Nicolas, L. Bodin, V. Jarlier, Y. Le Charpentier, J. Grosset, and P. Viars. 1992. Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis 146:1059-66.
123.    Pretet, S., A. Lebeaut, R. Parrot, C. Truffot, J. Grosset, and A. T. Dinh-Xuan. 1992. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection). Eur Respir J 5:680-4.
124.    Perronne, C., Y. Cohen, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1992. Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice. Antimicrob Agents Chemother 36:2408-12.
125.    Ji, B., E. G. Perani, C. Petinon, and J. H. Grosset. 1992. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. Int J Lepr Other Mycobact Dis 60:556-61.
126.    Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1992. Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agents Chemother 36:2839-40.
127.    Grosset, J. H. 1992. Treatment of tuberculosis in HIV infection. Tuber Lung Dis 73:378-83.
128.    Grosset, J., C. Truffot-Pernot, C. Lacroix, and B. Ji. 1992. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 36:548-51.
129.    Couderc, L. J., B. Epardeau, M. C. Dazza, J. P. Clauvel, B. Autran, J. Grosset, and I. Caubarrere. 1992. Disseminated Mycobacterium avium intracellulare infection without predisposing conditions. Lancet 340:731.
130.    Cohen, Y., C. Perronne, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1992. Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother 36:2104-7.
131.    Cartel, J. L., A. Spiegel, L. Nguyen Ngoc, J. P. Moulia-Pelat, P. M. Martin, and J. H. Grosset. 1992. Leprosy in French Polynesia. The possible impact of multidrug therapy on epidemiological trends. Lepr Rev 63:223-30.
132.    Cartel, J. L., S. Chanteau, J. P. Moulia-Pelat, R. Plichart, P. Glaziou, J. P. Boutin, J. F. Roux, and J. H. Grosset. 1992. Chemoprophylaxis of leprosy with a single dose of 25 mg per kg rifampin in the southern Marquesas; results after four years. Int J Lepr Other Mycobact Dis 60:416-20.
133.    Cartel, J. L., J. P. Boutin, A. Spiegel, P. Glaziou, R. Plichart, R. Cardines, and J. H. Grosset. 1992. Leprosy in French Polynesia. Epidemiological trends between 1946 and 1987. Lepr Rev 63:211-22.
134.    Truffot-Pernot, C., B. Ji, and J. Grosset. 1991. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle 72:57-64.
135.    Truffot-Pernot, C., B. Ji, and J. Grosset. 1991. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother 35:1677-8.
136.    Perronne, C., A. Gikas, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1991. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother 35:1356-9.
137.    Ji, B., C. Truffot-Pernot, and J. Grosset. 1991. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle 72:181-6.
138.    Ji, B., E. G. Perani, and J. H. Grosset. 1991. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 35:579-81.
139.    Ji, B., and J. Grosset. 1991. Ofloxacin for the treatment of leprosy. Acta Leprol 7:321-6.
140.    Dautzenberg, B., C. Truffot, A. Mignon, W. Rozenbaum, C. Katlama, C. Perronne, R. Parrot, and J. Grosset. 1991. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections a Mycobacteries Resistantes. Tubercle 72:168-75.
141.    Dautzenberg, B., C. Truffot, S. Legris, M. C. Meyohas, H. C. Berlie, A. Mercat, S. Chevret, and J. Grosset. 1991. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis 144:564-9.
142.    Constant-Desportes, M., C. C. Guelpa-Lauras, J. C. Carolina, A. Leoture, J. H. Grosset, and H. Sansarricq. 1991. A case of relapse with drug-susceptible M. leprae after multidrug therapy. Int J Lepr Other Mycobact Dis 59:242-7.
143.    Perronne, C., A. Gikas, C. Truffot-Pernot, J. Grosset, J. J. Pocidalo, and J. L. Vilde. 1990. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother 34:1508-11.
144.    N'Deli, L., C. C. Guelpa-Lauras, E. G. Perani, and J. H. Grosset. 1990. Effectiveness of pefloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis 58:12-8.
145.    Ji, B., and J. H. Grosset. 1990. Recent advances in the chemotherapy of leprosy. Lepr Rev 61:313-29.
146.    Grosset, J. H., B. H. Ji, C. C. Guelpa-Lauras, E. G. Perani, and L. N. N'Deli. 1990. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis 58:281-95.
147.    Grosset, J., H. Boisvert, C. Truffot-Pernot, and C. Rica. 1990. Organization of laboratory services in low prevalence countries, our personal view. Bull Int Union Tuberc Lung Dis 65:60-3.
148.    Grosset, J. 1990. New experimental regimens for preventive therapy of tuberculosis. Bull Int Union Tuberc Lung Dis 66:15-6.
149.    Grosset, J. 1990. [Bacteriologic basis for the treatment of tuberculosis]. Rev Prat 40:715-8.
150.    Grosset, J. 1990. Present and new drug regimens in chemotherapy and chemoprophylaxis of tuberculosis. Bull Int Union Tuberc Lung Dis 65:86-91.
151.    Grosset, J. 1990. [Norfloxacin: a broad-spectrum quinolone for superficial eye infections]. Pathol Biol (Paris) 38:735-41.
152.    Chanteau, S., J. L. Cartel, E. Perani, L. N'Deli, J. Roux, and J. H. Grosset. 1990. Relationships between PGL-1 antigen in serum, tissue and viability of Mycobacterium leprae as determined by mouse footpad assay in multibacillary patients during short-term clinical trial. Lepr Rev 61:330-40.
153.    Cartel, J. L., S. Chanteau, J. P. Boutin, R. Plichart, P. Richez, J. F. Roux, and J. H. Grosset. 1990. Assessment of anti-phenolic glycolipid-I IgM levels using an ELISA for detection of M. leprae infection in populations of the South Pacific Islands. Int J Lepr Other Mycobact Dis 58:512-7.
154.    Abel, L., V. V. Cua, J. Oberti, V. D. Lap, L. K. Due, J. Grosset, and P. H. Lagrange. 1990. Leprosy and BCG in southern Vietnam. Lancet 335:1536.
155.    Truffot-Pernot, C., H. F. Lecoeur, L. Maury, B. Dautzenberg, and J. Grosset. 1989. Results of blood cultures for detection of mycobacteria in AIDS patients. Tubercle 70:187-91.
156.    Rouby, J. J., M. D. Rossignon, M. H. Nicolas, E. Martin de Lassale, S. Cristin, J. Grosset, and P. Viars. 1989. A prospective study of protected bronchoalveolar lavage in the diagnosis of nosocomial pneumonia. Anesthesiology 71:679-85.
157.    Lecoeur, H. F., C. Truffot-Pernot, and J. H. Grosset. 1989. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 140:1189-93.
158.    Lecoeur, H. F., P. H. Lagrange, C. Truffot-Pernot, M. Gheorghiu, and J. Grosset. 1989. Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Clin Exp Immunol 76:458-62.
159.    Jarlier, V., M. H. Nicolas, A. Philippon, A. M. Giroir, and J. Grosset. 1989. In-vitro activity of FCE 22101 and other beta-lactam antibiotics against Enterobacteriaceae resistant to third generation cephalosporins. J Antimicrob Chemother 24:165-72.
160.    Grosset, J. H., and B. H. Ji. 1989. Controlled clinical trial for evaluation of antimicrobial drug activity against M. leprae. Int J Lepr Other Mycobact Dis 57:529-31.
161.    Grosset, J. H., C. C. Guelpa-Lauras, P. Bobin, G. Brucker, J. L. Cartel, M. Constant-Desportes, B. Flageul, M. Frederic, J. C. Guillaume, and J. Millan. 1989. Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int J Lepr Other Mycobact Dis 57:607-14.
162.    Grosset, J. H., J. Baohang, and S. K. Noordeen. 1989. Comments on an editorial by B. R. Chatterjee "On Multi-Drug Combinations in the Treatment of Leprosy". Indian J Lepr 61:323-7.
163.    Grosset, J. H. 1989. Present status of chemotherapy for tuberculosis. Rev Infect Dis 11:S347-52.
164.    Cartel, J. L., S. Chanteau, J. P. Boutin, R. Taylor, R. Plichart, J. Roux, P. Celerier, and J. H. Grosset. 1989. Implementation of chemoprophylaxis of leprosy in the Southern Marquesas with a single dose of 25 mg per kg rifampin. Int J Lepr Other Mycobact Dis 57:810-6.
165.    Truffot-Pernot, C., A. M. Giroir, L. Maury, and J. Grosset. 1988. [Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare]. Rev Mal Respir 5:401-6.
166.    Parrot, R. G., and J. H. Grosset. 1988. Post-surgical outcome of 57 patients with Mycobacterium xenopi pulmonary infection. Tubercle 69:47-55.
167.    Mitchison, D. A., G. A. Ellard, and J. Grosset. 1988. New antibacterial drugs for the treatment of mycobacterial disease in man. Br Med Bull 44:757-74.
168.    Lepetit, C., A. Thebaud-Mony, and J. Grosset. 1988. [Tuberculosis in the Department of Seine-Saint Denis. I. Cases under treatment in 1984]. Rev Mal Respir 5:129-36.
169.    Grosset, J. H., C. Truffot-Pernot, and H. Lecoeur. 1988. [New and future drugs in pulmonary tuberculosis]. Prax Klin Pneumol 42:206-10.
170.    Grosset, J. H., C. C. Guelpa-Lauras, E. G. Perani, and C. Beoletto. 1988. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis 56:259-64.
171.    Dautzenberg, B., and J. Grosset. 1988. [Tuberculosis and pregnancy]. Rev Mal Respir 5:279-83.
172.    Cartel, J. L., J. P. Boutin, R. Plichart, J. Roux, and J. H. Grosset. 1988. [Leprosy in the French Polynesian archipelagoes from 1967 to 1987]. Bull Soc Pathol Exot Filiales 81:819-26.
173.    Mouquet, C., J. Fusciardi, M. P. Stoupak, G. Vallancien, V. Jarlier, C. Chatelain, J. Grosset, and P. Viars. 1987. [Transurethral surgery and persistent urinary infection: effect of a single preoperative dose of cefuroxime]. Pathol Biol (Paris) 35:1243-7.
174.    McDermott-Lancaster, R. D., T. Ito, K. Kohsaka, C. C. Guelpa-Lauras, and J. H. Grosset. 1987. Multiplication of Mycobacterium leprae in the nude mouse, and some applications of nude mice to experimental leprosy. Int J Lepr Other Mycobact Dis 55:889-95.
175.    Guelpa-Lauras, C. C., E. G. Perani, A. M. Giroir, and J. H. Grosset. 1987. Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis 55:70-7.
176.    Grosset, J. H., and C. C. Guelpa-Lauras. 1987. Activity of rifampin in infections of normal mice with Mycobacterium leprae. Int J Lepr Other Mycobact Dis 55:847-51.
177.    Grosset, J. H., J. Baohong, and T. Ito. 1987. The first joint THELEP-Sasakawa Memorial Health Foundation workshop on experimental chemotherapy of leprosy. Int J Lepr Other Mycobact Dis 55:807-13.
178.    Grosset, J. H. 1987. Pharmacokinetics in drug screening. Int J Lepr Other Mycobact Dis 55:852-6.
179.    Grosset, J., and H. Lecoeur. 1987. [Present status of vaccination against leprosy]. Acta Leprol 5:231-9.
180.    Grosset, J., V. Jarlier, and H. Lecoeur. 1987. [BCG vaccination in France]. Rev Mal Respir 4:69-74.
181.    Grosset, J., C. C. Guelpa-Lauras, J. Millan, M. Bodian, and E. Perani. 1987. [Resistance of Mycobacterium leprae to dapsone and rifampicin: apropos of a survey carried out in the Cape Verde region (Senegal)]. Med Trop (Mars) 47:171-5.
182.    Cartel, J. L., Y. Naudillon, J. C. Remy, and J. H. Grosset. 1987. Contribution of relapses to total infection sources of leprosy in Guadeloupe. Lepr Rev 58:339-48.
183.    Soga, G., L. Blanc, C. Alfa, J. Grosset, and S. Xavier. 1986. [Combined treatments consisting of rifampicin in periodic doses: the experience in Niger]. Acta Leprol 4:397-407.
184.    Sebille, A., M. O. Crepon, C. C. Guelpa, and J. Grosset. 1986. [Electrophysiologic demonstration of the activity of rifampicin on nerve disease developing in mice inoculated with Hansen's bacilli in the footpad]. Acta Leprol 4:215.
185.    Millan, J., G. Roux, S. Loko, J. C. Naudin, P. Boucher, M. Bodian, M. Camara, T. Moreira-Diop, and J. Grosset. 1986. [Multi-drug therapy trials for leprosy in Senegal: first observations relative to liver tolerance of multibacillary patients. Therapeutic consequences]. Acta Leprol 4:427-44.
186.    Millan, J., M. Bodian, J. C. Naudin, B. Diouf, P. Boucher, B. Ndoye, and J. Grosset. 1986. [A trial of polychemotherapy of leprosy in the Dakar region. Initial observations on the acceptability of the protocols used]. Acta Leprol 4:19-35.
187.    Jarlier, V., C. J. Soussy, M. Chanal, D. Sirot, J. Le Van Thoi, R. Bismuth, J. Grosset, J. Duval, and R. Cluzel. 1986. [In vitro effect of piperacillin on aerobic bacteria. Variations according to the phenotypes of resistance to beta-lactam antibiotics]. Presse Med 15:2272-8.
188.    Grosset, J. H. 1986. Recent developments in the field of multidrug therapy and future research in chemotherapy of leprosy. Lepr Rev 57:223-34.
189.    Grosset, J., and H. Lecoeur. 1986. [Vaccination against leprosy]. Acta Leprol 4:289-91.
190.    Dautzenberg, B., C. Gallinari, G. Aeberhardt, A. Levy, J. Bernheim, J. Grosset, and C. Sors. 1986. [Routine use of 6-month antitubercular treatment in 300 patients]. Presse Med 15:2151-2, 2157-8.
191.    Constant-Desportes-Relouzat, M., J. Grosset, C. C. Guelpalauras, B. Salvini, and D. Cales-Quist. 1986. [Dynamics of establishing resistance of M. leprae to dapsone and rifampicin in Martinique]. Acta Leprol 4:293-300.
192.    Choudat, D., P. Horreard, S. Pretet, J. Grosset, and L. Toty. 1986. Superinfection by Aspergillus fumigatus of a pulmonary lesion caused by Mycobacterium xenopi. Tubercle 67:71-4.
193.    Cartel, J. L., J. J. Gallais, Y. Naudillon, J. G. Remy, and J. H. Grosset. 1986. [Epidemiology of leprosy in Guadeloupe from 1970 to 1984]. Acta Leprol 4:161-73.
194.    Cartel, J. C., J. J. Gallais, Y. Naudillon, J. Millan, and J. H. Grosset. 1986. [5-year assessment of daily multi-drug therapy of leprosy in Guadeloupe since 1980]. Acta Leprol 4:415-25.
195.    Sors, C., E. Bouvet, J. Grosset, S. Perdrizet, and S. Pretet. 1985. [Aspects of tuberculosis in France]. Rev Infirm 35:29-34.
196.    Sebille, A., M. O. Crepon, C. C. Guelpa, and J. Grosset. 1985. Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with Mycobacterium leprae. Int J Lepr Other Mycobact Dis 53:481-3.
197.    Nebout, M., and J. Grosset. 1985. [Present-day difficulties in the campaign against leprosy and proposals for its resumption in French-speaking Africa]. Acta Leprol 3:233-7.
198.    Grosset, J., C. Truffot-Pernot, S. Poggi, H. Lecoeur, and C. Chastang. 1985. [Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse]. Rev Mal Respir 2:205-8.
199.    Grosset, J., L. Levy, R. J. Rees, and C. C. Shepard. 1985. Drug sensitivity testing of M. leprae. Int J Lepr Other Mycobact Dis 53:118-21.
200.    Grosset, J. 1985. Bacteriological bases of short-course chemotherapy. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol 34:103-7.
201.    Grosset, J. 1985. Mechanisms of action of antituberculosis drugs in standard and short-course chemotherapy regimens. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol 34:108-15.
202.    Cartel, J. L., Y. Naudillon, J. C. Artus, and J. H. Grosset. 1985. Hepatotoxicity of the daily combination of 5 mg/kg prothionamide + 10 mg/kg rifampin. Int J Lepr Other Mycobact Dis 53:15-8.
203.    Cartel, J. L., Y. Naudillon, J. C. Artus, and J. H. Grosset. 1985. [Epidemiology of leprosy in Guadalupe between 1970 and 1983]. Bol Oficina Sanit Panam 98:535-47.
204.    Cartel, J. L., J. J. Gallais, and J. H. Grosset. 1985. [Acceptability, compliance and tolerance of daily polychemotherapy by leprosy patients in Guadeloupe]. Acta Leprol 3:339-55.
205.    Jarlier, V., C. Truffot-Pernot, and J. Grosset. 1984. [Potential value of the amoxicillin-clavulanic acid combination in general medicine, gynecology-obstetrics and pediatrics departments]. Pathol Biol (Paris) 32:492-5.
206.    Jarlier, V., R. Bismuth, M. H. Nicolas, J. Nguyen, C. Truffot, and J. Grosset. 1984. Survey of the phenotypes of susceptibility to beta-lactams in Enterobacteriaceae at the Pitie-Salpetriere Hospital. J Antimicrob Chemother 14:59-65.
207.    Guelpa-Lauras, C. C., J. H. Grosset, M. Constant-Desportes, and G. Brucker. 1984. Nine cases of rifampin-resistant leprosy. Int J Lepr Other Mycobact Dis 52:101-2.
208.    Grosset, J., and C. Sors. 1984. [Mycobacterioses]. Presse Med 13:215-8.
209.    Grosset, J. 1984. [Advances in the chemotherapy of leprosy]. Med Trop (Mars) 44:17-22.
210.    Giroulle, H., L. Bernabeu, H. Boisvert, C. Truffot, and J. Grosset. 1984. [Pulmonary mycobacteriosis due to a non-chromogenic, slow-growing, unclassified mycobacterium]. Rev Mal Respir 1:161-4.
211.    Dautzenberg, B., J. Grosset, J. Fechner, J. Lucciani, P. Debre, S. Herson, C. Truffot, and C. Sors. 1984. The management of thirty immunocompromised patients with tuberculosis. Am Rev Respir Dis 129:494-6.
212.    Truffot-Pernot, C., J. Grosset, R. Bismuth, and H. Lecoeur. 1983. [Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse]. Rev Fr Mal Respir 11:875-82.
213.    Parrot, R., C. Boval, J. Grosset, and J. P. Gaillard. 1983. [Adjusting or not adjusting isoniazid dosage?]. Rev Fr Mal Respir 11:705-12.
214.    Jarlier, V., R. Bismuth, and J. Grosset. 1983. [Cefotaxime, moxalactam and ceftriaxone: comparison of in vitro activity against hospital strains of Enterobacteriaceae belonging to the 4 principal phenotypes of sensitivity to beta-lactams]. Pathol Biol (Paris) 31:336-42.
215.    Grosset, J., C. Truffot-Pernot, H. Lecoeur, and C. C. Guelpa-Lauras. 1983. [Activity of rifampicin administered daily and intermittently on experimental tuberculosis in mice]. Pathol Biol (Paris) 31:446-50.
216.    Grosset, J., C. Truffot-Pernot, R. Bismuth, and H. Lecoeur. 1983. [Recent data on the chemotherapy of experimental tuberculosis in the mouse]. Bull Int Union Tuberc 58:90-6.
217.    Grosset, J., and S. Leventis. 1983. Adverse effects of rifampin. Rev Infect Dis 5:S440-50.
218.    Cooreman, J., G. Burghard, and J. Grosset. 1983. [Resistance of the Koch bacillus to antibacillary agents in the Department of the Lower Rhine]. Rev Fr Mal Respir 11:699-704.
219.    Cartel, J. L., J. Millan, C. C. Guelpa-Lauras, and J. H. Grosset. 1983. Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. Int J Lepr Other Mycobact Dis 51:461-5.
220.    Bismuth, R., V. Jarlier, and J. Grosset. 1983. [In vitro synergy between sulfamethoxazole and trimethoprim on strains of Staphylococcus aureus sensitive and resistant to methicillin]. Pathol Biol (Paris) 31:429-33.
221.    Sors, C., B. Dautzenberg, and J. Grosset. 1982. [Duration of the treatment of tuberculosis in 1981]. Nouv Presse Med 11:831.
222.    Nguyen, J., B. Dautzenberg, J. Grosset, and C. Sors. 1982. [Results of antibiotic sensitivity and "Streptococcus pneumoniae" serotype tests in the Pitie-Salpetriere hospital, France, 1979-1980 (author's transl)]. Rev Fr Mal Respir 10:115-20.
223.    Guelpa-Lauras, C. C., J. Grosset, C. Truffot-Pernot, and A. M. Giroir. 1982. [Comparative bactericidal action of rifampicin alone on M. tuberculosis and M. leprae]. Acta Leprol:69-75.
224.    Guelpa-Lauras, C. C., M. Constant-Desportes, J. Millan, and J. Grosset. 1982. [Resistance of Mycobacterium leprae to sulfones (DDS) and rifampicin in recurring lepromatous leprosy in Martinique and Guadeloupe since February 1980]. Acta Leprol:77-80.
225.    Grosset, J., and C. Truffot-Pernot. 1982. [Biology of the tubercle bacillus]. Rev Med Suisse Romande 102:257-63.
226.    Grosset, J., and C. Truffot-Pernot. 1982. [Laboratories: their role in the diagnosis and treatment of tuberculosis]. Bull Int Union Tuberc 57:234-41.
227.    Grosset, J., C. Truffot, J. Fermanian, and H. Lecoeur. 1982. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)]. Pathol Biol (Paris) 30:444-8.
228.    Grosset, J., C. Truffot, and C. Boval. 1982. The role of low dosage prothionamide with and without 4,4'-diamino diphenyl sulphone for use with isoniazid in the treatment of experimental mouse tuberculosis. Tubercle 63:37-43.
229.    Grosset, J., C. C. Guelpa-Lauras, and H. Lecoeur. 1982. [Current data on the bacteriology of leprosy]. Acta Leprol:35-45.
230.    Grosset, J., R. Bismuth, and J. Nguyen. 1982. [Pharmacokinetic basis for antibiotic therapy in broncho-pulmonary bacterial infections (author's transl)]. Rev Fr Mal Respir 10:195-203.
231.    Grosset, J. 1981. Studies in short-course chemotherapy for tuberculosis. Basis for short-course chemotherapy. Chest 80:719-20.
232.    Grosset, J. 1980. The efficacy of short-course chemotherapy for tuberculosis. Bull Pan Am Health Organ 14:139-49.
233.    Grosset, J. 1980. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1:231-41.
234.    Grosset, J. 1979. [The bacteriological principles of tuberculosis treatments]. Rev Prat 29:2645-50.
235.    Dautzenberg, B., J. Nguyen, J. Grosset, and C. Sors. 1979. [A comparative study of three procedures used for studying bronchopulmonary bacterial flora (author's transl)]. Ann Med Interne (Paris) 130:415-8.
236.    Pretet, S., J. Grosset, and S. Perdrizet. 1978. [Short term chemotherapy of tuberculosis. Evaluation of an 18-week-long treatment including pyrazinamide (preliminary results)]. Bull Int Union Tuberc 53:260-1.
237.    Grosset, J. 1978. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 53:5-12.
238.    Grosset, J. 1978. [Short term chemotherapy of tuberculosis. Current experimental findings in short term chemotherapy]. Bull Int Union Tuberc 53:281-3.
239.    Grosset, J., P. Glaser, A. Baud, and R. Bismuth. 1976. [Bacterial flora in pneumopathies and its significance in surgical resuscitation]. Lille Med 21:97-9.
240.    Vayssairat, M., R. Moulias, P. Rameix, J. Grosset, G. Chomette, and J. Loeper. 1973. [Two new cases of pulmonary mycobacteriosis due to Mycobacterium xenopi]. Ann Med Interne (Paris) 124:309-12.
241.    Canetti, G., M. Le Lirzin, P. Gay, R. Thibier, B. Kreis, and J. Grosset. 1972. [Primary resistance in adult pulmonary tuberculosis in France. 3d report of the study center on Primary Resistance: 1966-1970]. Rev Tuberc Pneumol (Paris) 36:337-56.
242.    Grosset, J., G. Decroix, and C. Sors. 1971. [Tuberculosis due to Mycobacterium africanum in African negroes in the Paris area]. Rev Tuberc Pneumol (Paris) 35:430-6.
243.    Grosset, J. 1971. Georges Canetti (1911-1971). Bull Int Union Tuberc 46:7-8.
244.    Boulahbal, F., and J. Grosset. 1971. [Use of pyridinium cetyl bromide as a transport medium for tuberculous sputum. Preliminary study]. Arch Inst Pasteur Alger 49:51-9.
245.    Larbaoui, D., P. Chaulet, J. Grosset, K. Abderrahim, and A. Zirout. 1970. [Controlled study of a bi-weekly treatment with isoniazid and ethionamide]. Bull Int Union Tuberc 43:282-8.
246.    Larbaoui, D., P. Chaulet, J. Grosset, K. Abderrahim, N. Oussedik, C. Coucke, and L. Benabdallah. 1970. [Intermittent treatment of "intractable chronic tuberculosis" by combined rifampicin-ethambutol: preliminary results of a controlled survey made in Algeria]. Rev Tuberc Pneumol (Paris) 34:559-66.
247.    Larbaoui, D., P. Chaulet, J. Grosset, K. Abderrahim, and H. Ait-Mesbah. 1970. The efficiency of methods of diagnosing pulmonary tuberculosis: an investigation in a chest clinic in Algiers. Tubercle 51:403-11.
248.    Grosset, J., and M. Benhassine. 1970. [Thiacetazone (Tb-1): recent experimental and clinical data]. Bibl Tuberc 26:107-53.
249.    de Beco, O., F. Boulahbal, and J. Grosset. 1970. [Incidence of the bovine bacillus in human tuberculosis at Algiers in 1969]. Arch Inst Pasteur Alger 48:93-101.
250.    Canetti, G., J. Grosset, and M. Le Lirzin. 1970. [Sterilization of tuberculous lesions under chemotherapy in humans. Main report]. Bull Int Union Tuberc 43:347-59.
251.    Seror, J., and J. Grosset. 1968. [Apropos of a case of mesenteric adenitis caused by Eberth's bacillus]. Ann Chir 22:629-31.
252.    Grosset, J., F. Rodrigues, M. Benhassine, P. Chaulet, and D. Larbaoui. 1968. Sensitivity to thiacetazone of strains of Mycobacterium tuberculosis isolated in Algiers: practical deductions. Tubercle 49:Suppl:46-8.
253.    Grosset, J., M. Benhassine, and L. Mokhtari. 1968. [Trial B.C.G. vaccination without previous tuberculin test in an Algiers outpatient clinic]. Rev Tuberc Pneumol (Paris) 32:551-60.
254.    Grosset, J., K. Abderrahim, P. Chaulet, and D. Larbaoui. 1968. [Results of bi-weekly treatment with isoniazid and streptomycine in 135 cases of pulmonary tuberculisis, in Algiers]. Bull Int Union Tuberc 41:325-30.
255.    Chaulet, P., M. Boulahbal, and J. Grosset. 1968. [Acquired resistance to antibiotics of the tuberculosis bacillus in the Algiers area from 1963 to 1967. Importance and epidemiologic significance]. Rev Tuberc Pneumol (Paris) 32:542-51.
256.    Chaulet, P., K. Abderrahim, J. Grosset, and D. Larbaoui. 1968. Clinical experience in Algeria of intermittent treatment of pulmonary tuberculosis with isoniazid and streptomycin twice-weekly. Tubercle 49:Suppl:81-2.
257.    Grumbach, F., G. Canetti, J. Grosset, and M. le Lirzin. 1967. Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model. Tubercle 48:11-26.
258.    Grosset, J., and M. Benhassine. 1967. [Antibiotic primary resistance of mycobacterium tuberculosis in hospitals in Algeria (1964-1966)]. Rev Tuberc Pneumol (Paris) 31:475-90.
259.    Chaulet, P., D. Larbaoui, J. Grosset, and K. Abderrahim. 1967. Intermittent chemotherapy with isoniazid and streptomycin in Algiers. Tubercle 48:128-36.
260.    Grumbach, F., G. Canetti, and J. Grosset. 1964. Further Experiments on Long-Term Chemotherapy of Advanced Murine Tuberculosis, with Emphasis on Intermittent Regimes. Tubercle 45:125-35.
261.    Canetti, G., N. Rist, and J. Grosset. 1964. Primary Drug Resistance in Tuberculosis. Am Rev Respir Dis 90:792-9.
262.    Canetti, G., B. Kreis, R. Thibier, J. Grosset, and J. Gluszyk. 1964. [Incidence and Characteristics of Primary Resistance in 2144 Cases of Untreated Pulmonary Tuberculosis from Different Regions of France. (Preliminary Report of the Centre D'etude Sur La R'esistance Primaire)]. Rev Tuberc Pneumol (Paris) 28:1115-58.
263.    Vivien, J. N., R. Thibier, A. Lepeuple, G. Canetti, and J. Grosset. 1963. [Systematic Determination of Active Isoniazid in the Blood Serum. (Data from a Series of 1,000 Patients)]. Rev Tuberc Pneumol (Paris) 27:1103-18.
264.    Thibier, R., A. Lepeuple, J. N. Vivien, and J. Grosset. 1963. [Results of Chemotherapy among 221 Patients with Pulmonary Tuberculosis Due to Bacilli Initially Sensitive to Principal Antibiotics (Follow up of 2 to 5 Years).]. Rev Tuberc Pneumol (Paris) 27:541-50.
265.    Lepeuple, A., R. Thibier, J. N. Vivien, G. Canetti, and J. Grosset. 1963. [Identification of the sources of contagion in various cases of primary tuberculosis resistance.]. Rev Tuberc Pneumol (Paris) 27:53-66.
266.    Canetti, G., N. Rist, and J. Grosset. 1963. [Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation.]. Rev Tuberc Pneumol (Paris) 27:217-72.
267.    Canetti, G., F. Grumbach, and J. Grosset. 1963. Long-term, two-stage chemotherapy of advanced experimental murine tuberculosis with intermittent regimes during the second stage. Tubercle 44:236-40.
268.    Canetti, G., S. Froman, J. Grosset, P. Hauduroy, M. Langerova, H. T. Mahler, G. Meissner, D. A. Mitchison, and L. Sula. 1963. Mycobacteria: Laboratory Methods for Testing Drug Sensitivity and Resistance. Bull World Health Organ 29:565-78.
269.    Thibier, R., G. Canetti, A. Lepeuple, J. Grosset, and J. N. Vivien. 1962. [Tuberculosis caused by primary-resistant bacilli in university students during the years 1958-1960.]. Bull Int Union Tuberc 32:113-7.
270.    Grosset, J., and G. Canetti. 1962. [Incidence of wild strains of Mycobacterium tuberculosis in variants resistant to minor antibiotics (p-aminosalicylic acid, ethionamide, cycloserine, viomycin, kanamycin).]. Ann Inst Pasteur (Paris) 103:163-84.
271.    Grosset, J., and G. Canetti. 1961. [Differences in the number of streptomycin-resistant variants in strains of Mycobacterium tuberculosis according to the type of streptomycin and the culture medium used.]. Ann Inst Pasteur (Paris) 101:234-52.
272.    Canetti, G., and J. Grosset. 1961. [Percentage of isoniazid-resistant and streptomycin-resistant variants in wild strains of Mycobacterium tuberculosis on Loewenstein-Jensen medium.]. Ann Inst Pasteur (Paris) 101:28-46.
273.    Thibier, R., G. Canetti, A. Lepeuple, J. Grosset, and J. N. Vivien. 1960. [Pulmonary tuberculosis with resistant bacilli in patients not yet treated.]. Riv Clin Pediatr 24:831-68.
274.    Lepeuple, A., R. Thibier, J. N. Vivien, J. Grosset, and G. Canetti. 1960. [A case of transmission of Koch bacilli from a tuberculous subject to a subject recovered from pulmonary tuberculosis.]. Riv Chir Pediatr 24:1312-21.
275.    Grumbach, F., J. Grosset, and G. Canetti. 1960. [The inactivation of isoniazid in the rat. Its effects on the results of the chemotherapy of tuberculosis in that species.]. Ann Inst Pasteur (Paris) 98:642-56.
276.    Grosset, J., and G. Canetti. 1960. [Complementary data on the determination of active isoniazid of the blood serum by the method of vertical diffusion. Determination in presence of PAS.]. Rev Tuberc Pneumol (Paris) 24:633-47.
277.    Canetti, G., F. Grumbach, and J. Grosset. 1960. Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid. Am Rev Respir Dis 82:295-313.
278.    Vivien, J. N., R. Thibier, J. Grosset, and A. Lepeuple. 1958. [Early results of isoniazid therapy as a function of the active blood level of isoniazid; study of 100 cases.]. Rev Tuberc 22:208-22.
279.    Grosset, J., G. Canetti, R. Thibier, J. N. Vivien, J. Lepeuple, and A. Saenz, Jr. 1958. [Comparative effects of oral and intravenous p-aminosalicylic acid on the active blood level of isoniazid.]. Rev Tuberc 22:202-7.
280.    Canetti, G., and J. Grosset. 1958. [Frequency of post-primary bronchial gland fistulas in 397 cases of pulmonary tuberculosis in adults treated by exeresis; discussion of their phthisiogenic role.]. Rev Tuberc 22:653-7.
281.    Canetti, G., and J. Grosset. 1956. [Late positivization of cultures of tuberculosis bacilli; its relation to isoniazid resistance.]. Rev Tuberc 20:1053-61.

 

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424

 

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer